Equity Profile

RPRX

Royalty Pharma plc

Health CarePharmaceuticals$24.2B

May6Wed

Pre-Earnings Brief

UpcomingQ1-2026Pre-Market9:00 AM EDT

Company Snapshot

Royalty Pharma plc (RPRX) is a leading player in the healthcare sector, focusing on acquiring and managing revenue-generating pharmaceutical royalties. With a market cap of $24 billion, the company plays a crucial role in funding the development of new therapies while providing investors with exposure to the pharmaceutical industry's growth potential.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$1.18

Revenue

Revenue figures reflect the company's ability to generate income from its royalty agreements, crucial for assessing growth.

$874M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RPRX Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

+5.28%

Avg Stock Reaction

+0.00%

Last Quarter Recap

In the last quarter, Royalty Pharma did not provide specific guidance, but historical performance indicates challenges in meeting earnings expectations. The company has a history of missing estimates, which may weigh on investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Royalty Pharma to report earnings of $1.18 per share on revenue of $874 million, reflecting steady performance amid a competitive landscape. The market is cautiously optimistic but wary of the company's historical earnings misses.

Bull Case

If Royalty Pharma exceeds earnings expectations, it could signal strong royalty income and effective management of its portfolio, potentially boosting investor confidence.

Bear Case

Conversely, if the company misses its earnings targets again, it may reinforce concerns about its ability to generate consistent revenue, leading to a negative market reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.18

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$874M

Revenue figures reflect the company's ability to generate income from its royalty agreements, crucial for assessing growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $1.18?

A beat on EPS could indicate stronger-than-expected revenue from royalties, which would be a positive signal for investors.

What are the revenue figures compared to the consensus of $874 million?

Revenue performance is critical for assessing the company's growth trajectory and ability to meet market expectations.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Royalty Pharma to capitalize on recent acquisitions and partnerships, which could drive revenue growth beyond expectations.

Supporting Evidence

Historical data shows that the company has occasionally outperformed expectations despite past misses.

The options market's implied move suggests that investors are bracing for volatility, which could indicate a surprise in either direction.

Key Risk

If the company reports revenue significantly above $874 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will help determine whether Royalty Pharma can stabilize its earnings and regain investor trust.

Bull Confirmed If

Exceeding $1.18 in EPS would confirm a strong operational performance and potentially lead to increased investor confidence.

Bear Confirmed If

Falling below the consensus revenue of $874 million would raise concerns about the company's growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±4.5%

The options market is pricing in a potential move of approximately 4.5% following the earnings report, indicating some uncertainty among investors.

Detail

30d HV

21.5%

Calls (400)P/C Ratio: 0.75Puts (300)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

84.49%

of float

Insider

7.12%

of float

Holders

844

institutions

Top Holders· as of Dec 2025

Morgan Stanley
55,274,069 sh · $2.7B
12.44%
25.2%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Royalty Pharma beats expectations, history suggests the stock could rise by an average of 2.89% on the day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns indicating an average drop of around 2.09% within five days.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new royalty agreements or partnerships that could impact revenue.
2Management's commentary on the performance of key drugs in their portfolio.
3Insights into the company's strategy for managing existing royalties.
4Any guidance on future earnings or revenue expectations.
5Responses to analyst questions regarding competitive pressures in the pharmaceutical space.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$1.18

Revenue

Revenue figures reflect the company's ability to generate income from its royalty agreements, crucial for assessing growth.

$874M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RPRX Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

+5.28%

Avg Stock Reaction

+0.00%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Royalty Pharma exceeds earnings expectations, it could signal strong royalty income and effective management of its portfolio, potentially boosting investor confidence.

Bear Case

Conversely, if the company misses its earnings targets again, it may reinforce concerns about its ability to generate consistent revenue, leading to a negative market reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.18

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$874M

Revenue figures reflect the company's ability to generate income from its royalty agreements, crucial for assessing growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $1.18?

A beat on EPS could indicate stronger-than-expected revenue from royalties, which would be a positive signal for investors.

What are the revenue figures compared to the consensus of $874 million?

Revenue performance is critical for assessing the company's growth trajectory and ability to meet market expectations.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Royalty Pharma to capitalize on recent acquisitions and partnerships, which could drive revenue growth beyond expectations.

Supporting Evidence

Historical data shows that the company has occasionally outperformed expectations despite past misses.

The options market's implied move suggests that investors are bracing for volatility, which could indicate a surprise in either direction.

Key Risk

If the company reports revenue significantly above $874 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will help determine whether Royalty Pharma can stabilize its earnings and regain investor trust.

Bull Confirmed If

Exceeding $1.18 in EPS would confirm a strong operational performance and potentially lead to increased investor confidence.

Bear Confirmed If

Falling below the consensus revenue of $874 million would raise concerns about the company's growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±4.5%

The options market is pricing in a potential move of approximately 4.5% following the earnings report, indicating some uncertainty among investors.

Detail

30d HV

21.5%

Calls (400)P/C Ratio: 0.75Puts (300)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

84.49%

of float

Insider

7.12%

of float

Holders

844

institutions

Top Holders· as of Dec 2025

Morgan Stanley
55,274,069 sh · $2.7B
12.44%
25.2%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Royalty Pharma beats expectations, history suggests the stock could rise by an average of 2.89% on the day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns indicating an average drop of around 2.09% within five days.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new royalty agreements or partnerships that could impact revenue.
2Management's commentary on the performance of key drugs in their portfolio.
3Insights into the company's strategy for managing existing royalties.
4Any guidance on future earnings or revenue expectations.
5Responses to analyst questions regarding competitive pressures in the pharmaceutical space.